Contact Information: Contacts: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs CEO to Present at 3rd Annual Stem Cell Summit in New York City
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - February 20, 2008) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) today
announced that the Company is scheduled to present at the 3rd Annual Stem
Cell Summit in New York City on Tuesday, February 26, 2008.
The Annual Stem Cell Summit is organized and produced by RRY Publications
and Robin Young Consulting. This year's Summit will feature more than 50
speakers, including a panel of stem cell patients. The goal of the Summit
is to bring together investors, industry executives, practitioners and
analysts to learn about investment opportunities in the stem cell
marketplace, groundbreaking stem cell products physicians are using today,
and the growing market potential in terms of revenues. For additional
information or to register, please visit www.stemcellsummit.com.
Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland
BioLabs, will give a brief presentation on the Company's Protectan CBLB612
compound at 10:44 a.m. ET on February 26.
Protectan CBLB612 is a modified lipopeptide mycoplasma that acts as a
powerful stimulator and mobilizer of hematopoietic (bone marrow/blood
production) stem cells (HSC) to peripheral blood. Potential applications
for CBLB612 include accelerated hematopoietic recovery during chemotherapy,
as well as during donor preparation for bone marrow transplantation.
Direct comparisons of Protectan CBLB612 and the market leading drug
used for stimulation of blood regeneration, G-CSF, demonstrated stronger
efficacy of CBLB612 as a propagator and mobilizer of HSC in peripheral
blood. CBLB612's unprecedented strength as a stem cell stimulator was
further demonstrated by the outcome of its combined use with G-CSF and
AMD3100 (a drug candidate emerging as a stem cell mobilizer), where the
addition of CBLB612 resulted in eight to ten times higher yields of HSC in
peripheral blood in comparison with the standard protocol.
With efficacy and non-GLP safety already studied in mice and monkeys,
CBLB612 entered formal pre-clinical safety and manufacturing development in
February 2008. Its first human trials are projected for 2009.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland
Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland
BioLabs, Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's periodic filings with the
Securities and Exchange Commission.